Perspectives

What AI Singularity Could Mean for the Future of Clinical Biometrics

Artificial Intelligence (AI) has moved well beyond theoretical speculation and is now driving meaningful transformation across clinical biometrics. As the concept of “AI singularity” approaches—where machine intelligence may rival or exceed human thinking—professionals in data management, biostatistics, and statistical programming are beginning to prepare for what this could mean for their roles and workflows.

At the 2025 PHUSE Single Day Event in Mississauga, Satya Ingle (Senior Manager, Statistical Programming at MMS) presented a vision for the future of biometrics, focusing on both the opportunities and the challenges that AI and AGI (Artificial General Intelligence) bring to the field. The following represents concepts described in his presentation in Ontario, Canada on October 24, 2025.

Understanding AI and AGI

AI tools today can mimic human decision-making within narrow tasks. Examples that people are more likely to encounter include chatbots, facial recognition, and automation of routine quality checks. These tools operate within clearly defined parameters and excel at repetitive or data-intensive assignments where rules are consistent.

AGI represents a different level entirely. This form of AI would be capable of carrying out any cognitive task that a human could perform. Imagine a tool that reads a clinical study protocol, selects endpoints, writes and validates code, and adapts based on prior data without needing step-by-step instruction.

See table 1 below for detailed examples.

Functions	AI	AGI
Data and Mapping	Rule-based, manual curation (CDISC)	Context-based reasoning across multiple sources, dynamic harmonization across standards
Adaptation of Trial Design	Manual, retraining needed for each protocol	Learns and adapts across trials
Sparse Data	Challenges in analysis	Infers patterns from limited data
Pattern Recognition	Correlation-based	Causal references across clinical variables
End-Point Prediction	Static models	Dynamic and personalized prediction of outcomes
Signals	Reactive	Proactively identifies emergent risk
Workflow	Task-specific	End-to-end automation
QC / Validation	Industry-standard double programming	Self-code validation with audit trail
Reusability & Repetitions	Specific generalization	Learns, creates, and uses macros across studies

This shift could redefine the role of biometrics professionals by turning them into supervisors of adaptive systems rather than doers of each task.

Current Impact Across Clinical Biometrics

AI is already improving workflows across the biometrics spectrum. In Clinical Data Management for instance, it supports auto-coding, reconciliation of queries, and understanding protocol logic. In Biostatistics, AI assists with modeling and statistical optimization. In Statistical Programming, AI can write and check code at a faster pace, helping improve data accuracy and reducing turnaround times.

These enhancements are already delivering real-time value in the form of speed, efficiency, and better utilization of an expert’s time. Rather than replacing people, these capabilities are helping teams work smarter and bridge resourcing gaps.

In this way, AI allows for better focus on strategic thinking and regulatory preparation.

Challenges and Considerations

Despite the promise of AI, adoption must be careful and deliberate. One major concern is the “black box” nature of deep learning models. When it is unclear how a model arrives at conclusions, regulatory trust becomes harder to establish, especially in the pharmaceutical and biotechnology industries.

Other challenges include:

Integration with outdated or rigid systems
Limited data availability for training
Shifting regulatory expectations
Maintaining data privacy and accountability

The solution comes in the form of transparency. AI outputs must be clearly documented and easy to validate. Human oversight remains essential. For sponsors and CROs, this means any AI implementation must align with their internal quality frameworks and external expectations from regulators.

Human and Machine, Together

Ingle encouraged the concept of Symbiotic Intelligence. AI can produce content, insights, and code. Humans must review, adjust, and guide the process. This balance ensures roles will grow rather than vanish.

This may look different in different professions. For instance: Data managers might take on interpretation roles; Statisticians may become strategic advisors, and; Programmers may oversee how AI tools function together.

This collaborative model is key to unlocking AI’s full value, augmenting human judgment rather than replacing it. It also reinforces the need for new skill sets in leadership, data ethics, and cross-functional communication.

Preparing for the Future

Biometrics professionals can take several steps to stay ahead, including:

Explore foundational AI and ML tools like Python, R, or Julia.
Join AI-focused work groups and kick off pilot projects.
Engage with regulators and industry on validation standards.
Test hybrid workflows that combine AI and traditional methods.

The future of clinical biometrics depends on how teams adopt and adapt. By combining human expertise with AI capabilities, organizations can increase efficiency, enhance data quality, and meet regulatory expectations with greater confidence. As Ingle put it, “With symbiosis, humans and machines will grow capabilities not even imagined.”

The industry’s future will reward those who are curious, flexible, and proactive in learning. Investing in AI literacy today ensures that pharma and biotech professionals can shape how these tools are used tomorrow.

To submit questions to Satya, message us here.

For further insights, read Smart AI, Smarter Oversight: What Sponsors Really Need from Their CRO.